Measurable Residual Disease Detected by Multiparameter Flow Cytometry and Sequencing Improves Prediction of Relapse and Survival in Acute Myeloid Leukemia
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Measurable Residual Disease Detected by Multiparameter Flow Cytometry and Sequencing Improves Prediction of Relapse and Survival in Acute Myeloid Leukemia
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-05-20
DOI
10.3389/fonc.2021.677833
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Molecular MRD status and outcome after transplantation in NPM1-mutated AML
- (2020) Richard Dillon et al. BLOOD
- Measurable residual disease monitoring provides insufficient lead-time to prevent morphologic relapse in the majority of patients with core-binding factor acute myeloid leukemia
- (2020) Robert Puckrin et al. HAEMATOLOGICA
- The loss or absence of minimal residual disease of
- (2020) Wenbing Duan et al. BRITISH JOURNAL OF HAEMATOLOGY
- MRD in AML: The Role of New Techniques
- (2019) Maria Teresa Voso et al. Frontiers in Oncology
- Measurable Residual Disease Monitoring in Acute Myeloid Leukemia with t(8;21)(q22;q22.1): Results of the AML Study Group
- (2019) Frank G. Rücker et al. BLOOD
- Next‐generation sequencing for measurable residual disease detection in acute myeloid leukaemia
- (2019) Jack Ghannam et al. BRITISH JOURNAL OF HAEMATOLOGY
- Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
- (2018) Gerrit J. Schuurhuis et al. BLOOD
- Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information
- (2018) Paola Minetto et al. BRITISH JOURNAL OF HAEMATOLOGY
- Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations
- (2018) Sylvie D. Freeman et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Minimal Residual Disease in Acute Myeloid Leukemia
- (2018) Mojca Jongen-Lavrencic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acute myeloid leukaemia
- (2018) Nicholas J Short et al. LANCET
- Minimal/Measurable Residual Disease Monitoring in NPM1-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives
- (2018) Fabio Forghieri et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Minimal residual disease in acute myelogenous leukemia
- (2017) N. M. Cruz et al. International Journal of Laboratory Hematology
- Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group
- (2017) Marie Balsat et al. JOURNAL OF CLINICAL ONCOLOGY
- Measurable residual disease testing in acute myeloid leukaemia
- (2017) C S Hourigan et al. LEUKEMIA
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
- (2016) Hartmut Döhner et al. BLOOD
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- Assessment of Minimal Residual Disease in Standard-Risk AML
- (2016) Adam Ivey et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia
- (2015) Jeffery M. Klco et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Postremission sequential monitoring of minimal residual disease by WT1 Q-PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk-adapted therapy in acute myeloid leukemia patients
- (2015) Michele Malagola et al. Cancer Medicine
- Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide
- (2015) Yang Shen et al. EBioMedicine
- Predictive role of minimal residual disease and log clearance in acute myeloid leukemia: a comparison between multiparameter flow cytometry and Wilm’s tumor 1 levels
- (2014) Giovanni Rossi et al. ANNALS OF HEMATOLOGY
- Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?
- (2014) D. Grimwade et al. BLOOD
- In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification
- (2014) Y. Wang et al. BLOOD
- The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML
- (2013) N. Shayegi et al. BLOOD
- Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia
- (2013) E. Jourdan et al. BLOOD
- High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study
- (2013) Monique Terwijn et al. JOURNAL OF CLINICAL ONCOLOGY
- Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia
- (2013) Carlo Marani et al. LEUKEMIA RESEARCH
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic significance of monitoring leukemia-associated immunophenotypes by eight-color flow cytometry in adult B-acute lymphoblastic leukemia
- (2013) X-Q Weng et al. Blood Cancer Journal
- Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial
- (2012) J. A. L. Yin et al. BLOOD
- Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia
- (2011) Y. Shen et al. BLOOD
- Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity
- (2010) E. Taskesen et al. BLOOD
- Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by StandardizedWT1Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study
- (2009) Daniela Cilloni et al. JOURNAL OF CLINICAL ONCOLOGY
- Prospective Minimal Residual Disease Monitoring to Predict Relapse of Acute Promyelocytic Leukemia and to Direct Pre-Emptive Arsenic Trioxide Therapy
- (2009) David Grimwade et al. JOURNAL OF CLINICAL ONCOLOGY
- The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse
- (2008) Adhra Al-Mawali et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now